IL274229B2 - Antibacterial compounds - Google Patents
Antibacterial compoundsInfo
- Publication number
- IL274229B2 IL274229B2 IL274229A IL27422920A IL274229B2 IL 274229 B2 IL274229 B2 IL 274229B2 IL 274229 A IL274229 A IL 274229A IL 27422920 A IL27422920 A IL 27422920A IL 274229 B2 IL274229 B2 IL 274229B2
- Authority
- IL
- Israel
- Prior art keywords
- 4alkyl
- group
- nrr
- phenyl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Warehouses Or Storage Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1718285.8A GB201718285D0 (en) | 2017-11-03 | 2017-11-03 | Antibacterial Compounds |
| PCT/GB2018/053183 WO2019086890A1 (en) | 2017-11-03 | 2018-11-02 | Antibacterial compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL274229A IL274229A (en) | 2020-06-30 |
| IL274229B1 IL274229B1 (en) | 2023-01-01 |
| IL274229B2 true IL274229B2 (en) | 2023-05-01 |
Family
ID=60664899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274229A IL274229B2 (en) | 2017-11-03 | 2020-04-26 | Antibacterial compounds |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11345694B2 (enExample) |
| EP (2) | EP3704105B9 (enExample) |
| JP (2) | JP7348897B2 (enExample) |
| KR (1) | KR102470319B1 (enExample) |
| CN (1) | CN111566099B (enExample) |
| AU (1) | AU2018361828B2 (enExample) |
| BR (1) | BR112020008531A2 (enExample) |
| CA (1) | CA3081423A1 (enExample) |
| CL (2) | CL2020001147A1 (enExample) |
| CO (1) | CO2020005420A2 (enExample) |
| EA (1) | EA202091118A1 (enExample) |
| ES (1) | ES3005164T3 (enExample) |
| GB (1) | GB201718285D0 (enExample) |
| GE (1) | GEP20237522B (enExample) |
| IL (1) | IL274229B2 (enExample) |
| MA (1) | MA50504A (enExample) |
| MX (2) | MX2020004562A (enExample) |
| NZ (1) | NZ764310A (enExample) |
| PE (2) | PE20211390A1 (enExample) |
| SG (1) | SG11202003717UA (enExample) |
| UA (1) | UA128475C2 (enExample) |
| WO (1) | WO2019086890A1 (enExample) |
| ZA (1) | ZA202002093B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
| HUE066783T2 (hu) | 2018-04-18 | 2024-09-28 | Constellation Pharmaceuticals Inc | Metil módosító enzimek modulátorai, ezek készítményei és alkalmazásuk |
| WO2019226491A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN111635372B (zh) * | 2020-06-28 | 2022-05-27 | 齐鲁工业大学 | 一种恶唑酮衍生物及其合成方法 |
| EP4333854A1 (en) * | 2021-05-03 | 2024-03-13 | Discuva Ltd. | Antibacterial compound |
| EP4484609A1 (en) | 2022-02-21 | 2025-01-01 | Mitsui Chemicals, Inc. | Metal member, metal-resin composite body, and method for producing metal member |
| CN120208965B (zh) * | 2025-05-28 | 2025-08-12 | 四川大学 | 靶向革兰氏阴性菌外膜组装关键蛋白质机器的4-(吡啶-4-基)-1h-咪唑-2-胺类衍生物、组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA869348B (en) | 1985-12-12 | 1987-10-28 | Smithkline Beckman Corp | Inhibition of the 5-lipoxygenase pathway |
| US4780470A (en) * | 1986-08-19 | 1988-10-25 | Smithkline Beckman Corporation | Inhibition of interleukin-1 by monocytes and/or macrophages |
| JP2808460B2 (ja) * | 1989-11-16 | 1998-10-08 | 大正製薬株式会社 | イミダゾール誘導体 |
| JPH09124640A (ja) | 1995-08-25 | 1997-05-13 | Nippon Soda Co Ltd | ピリジルイミダゾール化合物、製法および農園芸用殺菌剤 |
| US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| AR029803A1 (es) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| EP1532118A2 (en) * | 2002-07-05 | 2005-05-25 | Axxima Pharmaceuticals Aktiengesellschaft | Imidazole compounds for the treatment of hepatitis c virus infections |
| JP2004196678A (ja) | 2002-12-17 | 2004-07-15 | Dainippon Pharmaceut Co Ltd | ピラゾール系誘導体 |
| WO2005047266A1 (en) | 2003-11-14 | 2005-05-26 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| WO2005085241A1 (ja) * | 2004-03-05 | 2005-09-15 | Taisho Pharmaceutical Co., Ltd. | チアゾール誘導体 |
| JP2007277230A (ja) * | 2006-03-15 | 2007-10-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| EP2513064B1 (en) * | 2009-12-17 | 2018-07-04 | Katholieke Universiteit Leuven K.U. Leuven R&D | Compounds, compositions and methods for controlling biofilms |
| GB201016261D0 (en) | 2010-09-28 | 2010-11-10 | Univ Leuven Kath | Compounds for controlling biofilms and process for their production |
| WO2012135016A2 (en) | 2011-03-25 | 2012-10-04 | North Carolina State University | Inhibition of bacterial biofilms and microbial growth with imidazole derivatives |
| PL2731949T3 (pl) * | 2011-07-13 | 2018-10-31 | Tiumbio Co., Ltd. | 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4 |
| US8840912B2 (en) | 2012-01-09 | 2014-09-23 | North Carolina State University | Imidazole derivatives useful for controlling microbial growth |
| KR102405136B1 (ko) * | 2014-05-16 | 2022-06-07 | 아트리바 테라퓨틱스 게엠베하 | 인플루엔자 바이러스 및 에스. 아우레우스 공감염에 대한 신규한 항-감염 전략 |
| KR20170122799A (ko) | 2015-03-02 | 2017-11-06 | 리겔 파마슈티칼스, 인크. | TGF-β 억제제 |
| US20180044316A1 (en) | 2015-03-05 | 2018-02-15 | University Of Notre Dame Du Lac | Potentiators of beta-lactam antibiotics |
| CA3030582A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
-
2017
- 2017-11-03 GB GBGB1718285.8A patent/GB201718285D0/en not_active Ceased
-
2018
- 2018-11-02 NZ NZ764310A patent/NZ764310A/en unknown
- 2018-11-02 MA MA050504A patent/MA50504A/fr unknown
- 2018-11-02 PE PE2020000454A patent/PE20211390A1/es unknown
- 2018-11-02 SG SG11202003717UA patent/SG11202003717UA/en unknown
- 2018-11-02 EP EP18800297.6A patent/EP3704105B9/en active Active
- 2018-11-02 WO PCT/GB2018/053183 patent/WO2019086890A1/en not_active Ceased
- 2018-11-02 BR BR112020008531-6A patent/BR112020008531A2/pt active Search and Examination
- 2018-11-02 CN CN201880085171.5A patent/CN111566099B/zh active Active
- 2018-11-02 PE PE2022000118A patent/PE20221006A1/es unknown
- 2018-11-02 CA CA3081423A patent/CA3081423A1/en active Pending
- 2018-11-02 US US16/761,016 patent/US11345694B2/en active Active
- 2018-11-02 EA EA202091118A patent/EA202091118A1/ru unknown
- 2018-11-02 MX MX2020004562A patent/MX2020004562A/es unknown
- 2018-11-02 GE GEAP201815801A patent/GEP20237522B/en unknown
- 2018-11-02 EP EP24200101.4A patent/EP4606375A3/en active Pending
- 2018-11-02 UA UAA202003341A patent/UA128475C2/uk unknown
- 2018-11-02 ES ES18800297T patent/ES3005164T3/es active Active
- 2018-11-02 KR KR1020207015574A patent/KR102470319B1/ko active Active
- 2018-11-02 JP JP2020524275A patent/JP7348897B2/ja active Active
- 2018-11-02 AU AU2018361828A patent/AU2018361828B2/en active Active
-
2020
- 2020-04-26 IL IL274229A patent/IL274229B2/en unknown
- 2020-04-30 CL CL2020001147A patent/CL2020001147A1/es unknown
- 2020-04-30 CO CONC2020/0005420A patent/CO2020005420A2/es unknown
- 2020-05-04 ZA ZA2020/02093A patent/ZA202002093B/en unknown
- 2020-07-13 MX MX2021010246A patent/MX2021010246A/es unknown
-
2021
- 2021-08-27 CL CL2021002263A patent/CL2021002263A1/es unknown
- 2021-11-01 JP JP2021178557A patent/JP2022025116A/ja not_active Withdrawn
-
2022
- 2022-04-25 US US17/728,335 patent/US20220372027A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274229B1 (en) | Antibacterial compounds | |
| IL275762B1 (en) | Derivatives of phenyl-so2-nh-c(=o)-phenyl-piperazine-ch2-1,2-cyclohexane-bicyclo[1.1.1]pentane and pharmaceutical compositions comprising them | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2017511360A5 (enExample) | ||
| RU2018129308A (ru) | Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их | |
| RU2018102365A (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| EA201791727A1 (ru) | 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| JP2019517487A5 (enExample) | ||
| WO2018155916A3 (ko) | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| JP2019504050A5 (enExample) | ||
| PH12017501699B1 (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| RU2016134751A (ru) | Соединения | |
| FI4003532T3 (fi) | 7-kloori-2-(4-(3-metoksiatsetidin-1-yyli)sykloheksyyli)-2,4-dimetyyli-n-((6-metyyli-4-(metyylitio)-2-okso-1,2-dihydropyridin-3-yyli)metyyli)bentso[d][1,3]dioksoli-5-karboksamidin kiteisiä muotoja | |
| RU2019142111A (ru) | Усилитель противоопухолевого эффекта с применением нового соединения бифенила | |
| PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
| JP2021501756A5 (enExample) | ||
| MY206359A (en) | Heteroaryl-substituted pyrazole compound and medicinal use thereof | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| ZA202203107B (en) | Azaindole carboxamide compounds for the treatment of mycobacterial infections | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| RU2015155032A (ru) | Тилозиновые производные и способ их получения | |
| MX2020013847A (es) | Forma cristalina del compuesto para inhibir la actividad de cdk4/6 y uso del mismo. |